- Home
- RAMP vs SPRY Comparison
RAMP vs SPRY Comparison
Compare RAMP & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- SPRY
- Stock Information
- Founded
- RAMP 2018
- SPRY 2015
- Country
- RAMP United States
- SPRY United States
- Employees
- RAMP N/A
- SPRY N/A
- Industry
- RAMP EDP Services
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- RAMP Technology
- SPRY Health Care
- Exchange
- RAMP Nasdaq
- SPRY Nasdaq
- Market Cap
- RAMP 1.8B
- SPRY 1.8B
- IPO Year
- RAMP 1987
- SPRY N/A
- Fundamental
- Price
- RAMP $28.38
- SPRY $10.07
- Analyst Decision
- RAMP Buy
- SPRY Strong Buy
- Analyst Count
- RAMP 7
- SPRY 5
- Target Price
- RAMP $39.00
- SPRY $31.00
- AVG Volume (30 Days)
- RAMP 769.2K
- SPRY 3.0M
- Earning Date
- RAMP 11-05-2025
- SPRY 08-13-2025
- Dividend Yield
- RAMP N/A
- SPRY N/A
- EPS Growth
- RAMP 147.00
- SPRY N/A
- EPS
- RAMP 0.22
- SPRY N/A
- Revenue
- RAMP $764,441,000.00
- SPRY $112,339,000.00
- Revenue This Year
- RAMP $10.65
- SPRY N/A
- Revenue Next Year
- RAMP $8.70
- SPRY $182.40
- P/E Ratio
- RAMP $147.94
- SPRY N/A
- Revenue Growth
- RAMP 12.16
- SPRY 22367.80
- 52 Week Low
- RAMP $22.82
- SPRY $9.97
- 52 Week High
- RAMP $36.08
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- RAMP 49.74
- SPRY 20.04
- Support Level
- RAMP $26.89
- SPRY $10.98
- Resistance Level
- RAMP $28.15
- SPRY $14.00
- Average True Range (ATR)
- RAMP 0.67
- SPRY 0.80
- MACD
- RAMP 0.31
- SPRY -0.36
- Stochastic Oscillator
- RAMP 85.66
- SPRY 1.95
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.